Title:
TOPICAL APPLICATION OF ALPHA-DFMO AND ANTI-INFLAMMATORY DRUG FOR TREATMENT OF ACTINIC KERATOSES
Document Type and Number:
WIPO Patent Application WO2003057172
Kind Code:
A3
Abstract:
Topical alpha-DFMO is mixed with a hydrophillic ointment base, along with at least one additional active drug, for treating actinic keratoses by topical application to human skin tissues. In one case, the topical steroid triamcinolone is combined with the alpha-DFMO. In a second case, the topical non-steroid anti-inflammatory diclofenac is combined with the alpha-DFMO. In a third instance, both triamcinolone and diclofenac are combined with the alpha-DFMO. In all such instances, topical application of such combinations was found to inhibit squamous cell cancer, and the combined effect of such components, when selected in appropriate proportions, in inhibiting squamous cell cancer cells is significantly greater than the effectiveness of each such component by itself.
Inventors:
ALBERTS DAVID S
DORR ROBERT T
DORR ROBERT T
Application Number:
PCT/US2003/000375
Publication Date:
December 31, 2003
Filing Date:
January 07, 2003
Export Citation:
Assignee:
TOPICAL TECHNOLOGIES INC (US)
International Classes:
A61K31/198; A61K31/573; A61K45/06; (IPC1-7): A61K9/00; A61K31/195
Foreign References:
| US5851537A | 1998-12-22 | |||
| US6258845B1 | 2001-07-10 |
Other References:
DATABASE CA [online] LOWE ET AL.: "Inhibition of ultraviolet-B ornithine decarboxylase induction and skin carcinogenesis in hairless mice by topical indomethacin and triamcinolone acetonide", XP002967104, accession no. STN Database accession no. 1982:574633
Download PDF:
Previous Patent: ACTIVATION AND EXPANSION OF T-CELLS USING AN ENGINEERED MULTIVALENT SIGNALING PLATFORM
Next Patent: BROAD SPECTRUM INHIBITORS
Next Patent: BROAD SPECTRUM INHIBITORS